跳至主要内容
临床试验/ACTRN12613000946718
ACTRN12613000946718尚未招募2 期

Peg-interferon-alfa to achieve HBsAg loss in multi-drug resistance HBV under long-term viral suppression with tenofovir DF +/- lamivudine salvage therapy

Peter Angus0 个研究点目标入组 55 人开始时间: 2013年8月27日最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
55

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • The initial TF109 has not been registered on ANZCTR. The initial 2 year data has been published by Patterson SJ, George J, Strasser SI, Lee AU, Sievert W, Nicoll AJ, et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut. 2011;60:247-54. The key inclusion criteria is that they have to have been involved in the initial TF109 study - on long term tenofovir DF.

排除标准

  • Severe liver disease which excludes them from peg-interferon therapy.

研究者

发起方
Peter Angus

相似试验